230 related articles for article (PubMed ID: 14532138)
1. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Dougados M; Emery P; Gibofsky A; Kavanaugh AF; Keystone EC; Klareskog L; Russell AS; van de Putte LB; Weisman MH
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii2-9. PubMed ID: 14532138
[No Abstract] [Full Text] [Related]
2. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Emery P; Keystone EC; Schiff MH; van Riel PL; Weinblatt ME; Weisman MH
Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii2-15. PubMed ID: 17038465
[No Abstract] [Full Text] [Related]
3. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Furst DE; Keystone EC; Kirkham B; Kavanaugh A; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Burmester GR; Braun J; Emery P; Winthrop K; Bresnihan B; De Benedetti F; Dörner T; Gibofsky A; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii2-25. PubMed ID: 19022808
[No Abstract] [Full Text] [Related]
4. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.
Pressman Lovinger S
JAMA; 2003 Jun; 289(24):3229-30. PubMed ID: 12824197
[No Abstract] [Full Text] [Related]
5. Rheumatoid arthritis and tuberculosis in the tumor necrosis factor inhibitors era: observations from Brazil.
da Rocha Castelar Pinheiro G
J Clin Rheumatol; 2005 Dec; 11(6):344-6. PubMed ID: 16371812
[No Abstract] [Full Text] [Related]
6. Drugs for rheumatoid arthritis.
Treat Guidel Med Lett; 2012 May; 10(117):37-44; quiz 2 p following 44. PubMed ID: 22538522
[No Abstract] [Full Text] [Related]
7. Management of rheumatoid arthritis.
Handa R
Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
[TBL] [Abstract][Full Text] [Related]
8. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
[No Abstract] [Full Text] [Related]
9. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
[TBL] [Abstract][Full Text] [Related]
10. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
[No Abstract] [Full Text] [Related]
11. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.
Rajakulendran S; Gadsby K; Allen D; O'Reilly S; Deighton C
Ann Rheum Dis; 2006 Dec; 65(12):1678-9. PubMed ID: 17105865
[No Abstract] [Full Text] [Related]
12. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
Finucane KA; Archer CB
Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
[No Abstract] [Full Text] [Related]
13. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
14. Perioperative management of biologic agents used in treatment of rheumatoid arthritis.
Mushtaq S; Goodman SM; Scanzello CR
Am J Ther; 2011 Sep; 18(5):426-34. PubMed ID: 20216205
[TBL] [Abstract][Full Text] [Related]
15. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
16. When is switching warranted among biologic therapies in rheumatoid arthritis?
Reynolds A; Koenig AS; Bananis E; Singh A
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):319-33. PubMed ID: 22812556
[TBL] [Abstract][Full Text] [Related]
17. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i2-36. PubMed ID: 21339216
[No Abstract] [Full Text] [Related]
18. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Antoni CE; Bijlsma JW; Burmester GR; Cronstein B; Keystone EC; Kavanaugh A; Klareskog L
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii2-7. PubMed ID: 12379612
[No Abstract] [Full Text] [Related]
19. Advances in targeted therapy: safety of biological agents.
Keystone EC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii34-6. PubMed ID: 14532146
[No Abstract] [Full Text] [Related]
20. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).
Furst DE; Breedveld FC; Burmester GR; Crofford JJ; Emery P; Feldmann M; Kalden JR; Kavanaugh AF; Keystone EC; Klareskog LG; Lipsky PE; Maini RN; Russell AS; Scott DL; Smolen JS; Van de Putte LB; Visher TL; Weisman MH
Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i1-2. PubMed ID: 11053077
[No Abstract] [Full Text] [Related]
[Next] [New Search]
